查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984154

腦造影市場：2026-2032年全球市場預測（按診斷方法、患者類型、應用和最終用戶分類）

Brain Imaging Modalities Market by Modality, Patient Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腦造影市場價值將達到 153.7 億美元，到 2026 年將成長至 169 億美元，到 2032 年將達到 310.4 億美元，複合年成長率為 10.55%。

主要市場統計數據
基準年 2025 153.7億美元
預計年份：2026年 169億美元
預測年份 2032 310.4億美元
複合年成長率 (%) 10.55%

權威概述了現代腦部影像技術，以及各種影像方式的融合如何改變臨床護理和神經科學研究的進程。

腦部影像研究已發展成為一門跨學科領域，涵蓋臨床神經病學、外科醫學、神經科學研究和生物醫學工程等多個學科。設備、數據分析和示蹤化學技術的進步，不僅拓展了可用的影像方式，也提高了臨床醫師診斷、監測和治療神經系統疾病的準確性。因此，影像技術如今已應用於各個領域，從急性介入方案的發展到長期治療監測，甚至包括對基本機制的闡明。

人工智慧、攜帶式設備、混合成像示蹤劑和互通分析技術的進步如何改變臨床實踐、調查工作流程和診斷信心。

在技​​術創新、資料科學和不斷變化的臨床需求的驅動下，腦造影領域正經歷著許多變革。人工智慧和先進的影像分析技術如今已能與人類解讀相輔相成，顯著提升了檢測細微病理學變化的能力，並使得提取以往無法獲得的定量生物標記成為可能。同時，高場磁振造影（HMRI）、緊湊型電腦斷層掃描器）和攜帶式超音波設備等硬體創新，正在拓展診斷影像的施行地點，使診斷能力更貼近臨床實務。

評估 2025 年關稅環境將如何影響腦部影像診斷相關人員的供應可靠性、籌資策略和研究連續性。

2025年關稅調整帶來的政策轉變對全球腦部影像硬體、耗材及配套服務的供應鏈產生了顯著的連鎖反應。對特殊零件提高進口關稅，延長了大型設備和間歇性供應零件的前置作業時間，迫使製造商和醫療系統調整籌資策略。因此，採購週期延長，企業必須在資本規劃中預留更大的儲備金，以維持計畫中的升級和安裝。

透過整合模態差異、應用需求和最終用戶限制的詳細細分分析，指導採購、研發和臨床引入策略。

基於分割的洞察揭示了在成像方式、應用和最終用戶維度上，技術採納、臨床效用和研究投入分配方面的微妙模式。就影像方式而言，情況包括電腦斷層掃描 (CT)、磁振造影(MRI)、光學成像、正子斷層掃描 (PET)、單光子發射電腦斷層掃描 (SPECT) 和超音波影像。在電腦斷層掃描 (CT) 中，錐狀射束CT 與傳統系統的差異會影響介入和手術導航的選擇。同時，磁振造影(MRI) 又細分為血管造影術、擴散影像、功能性影像和結構影像技術，以支援血管、白質、功能連接和解剖結構評估。類似地，光學影像包括功能性近紅外線光譜和光學同調斷層，而正子斷層掃描則區分澱粉樣蛋白、多巴胺和 FDG 等追蹤劑。另一方面，單光子發射電腦斷層掃描通常專注於多巴胺轉運體成像。超音波成像技術仍分為兩類：一類是用於高解析度眼科和淺層組織應用的生物顯微鏡，另一類是用於血流動力學監測的經顱都卜勒超音波。

區域策略分析，重點關注美洲、歐洲、中東和非洲以及亞太地區在採用率、法規、基礎設施和供應鏈本地化方面的差異。

區域趨勢正在塑造美洲、歐洲、中東和非洲（EMEA）以及亞太地區不同的技術採納曲線、監管時間表、基礎設施投資和供應鏈韌性。在美洲，醫療保健整合、高水準的私人投資和完善的報銷機制正在推動先進影像技術的快速普及，尤其是在三級醫療中心和研究中心。同時，該地區面臨著最佳化資本週期和強調基於價值的採購的日益成長的壓力，因此更加關注那些能夠展現明確成果和營運效率的解決方案。

企業策略、夥伴關係和平台方法如何整合，以加速先進腦部影像解決方案的檢驗和商業性部署。

腦部影像生態系統的企業發展趨勢是能力融合、策略夥伴關係以及旨在彌合臨床差距的定向創新。成熟的醫療設備製造商繼續優先發展先進的影像處理、人工智慧成像以及將設備與全生命週期支援捆綁在一起的服務模式。同時，專業供應商和Start-Ups則專注於示蹤劑開發、光學成像模組或高階後處理分析等細分領域，以滿足尚未滿足的臨床和研究需求，從而創造價值。

為幫助高階主管和臨床領導者增強韌性、檢驗創新並安全地實施診斷影像技術的進步，提供實際有效的建議。

產業領導者應採取務實、行動導向的策略，在短期業務永續營運和長期臨床創新之間取得平衡。首先，應實現採購和製造合作夥伴多元化，以降低供應鏈中斷和政策變化帶來的風險，同時投資於庫存視覺化工具，從而實現主動採購。其次，在選擇成像硬體和軟體時，應優先考慮互通性和標準合規性，以保護未來的投資並簡化多中心研究合作。

我們採用綜合性的多方法研究框架，結合文獻整合、專家訪談、工具性證據和情境分析，為策略決策提供支援。

本研究採用整合多種證據來源的方法，對目前腦部影像技術現況進行穩健且有力的分析。主要調查方法包括系統性地回顧同行評審文獻、監管文件和臨床試驗註冊資訊，以及與臨床專家、成像科學家、採購負責人和技術供應商進行結構化訪談。這種綜合分析利用儀器性能規格、示踪劑化學表徵報告和運行案例研究，將技術能力與臨床和研究應用案例相匹配。

簡明扼要地整合了影響腦部影像臨床和研究成功的技術進步、營運挑戰和策略重點。

總之，影像硬體、示蹤劑化學和分析技術的進步正在拓展臨床醫生和科學家可用的診斷和研究能力。這些進步為更精確的疾病表徵、改進的手術計劃和可靠的治療監測創造了機會，但也要求在互通性、檢驗和人力資源準備方面進行有意識的投入。政策趨勢和供應鏈的變化凸顯了多樣化籌資策略以及供應商和臨床操作人員之間更緊密合作的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：腦部影像市場：依影像方式分類

  • 電腦斷層掃描
    • 錐狀射束
    • 傳統的
  • 磁振造影
    • 血管造影術
    • 擴散
    • 功能性
    • 結構
  • 光學成像
    • FNIRS
    • 光學同調斷層掃描
  • 正子斷層掃描
    • 澱粉樣蛋白
    • 多巴胺
    • FDG
  • 單光子發射電腦斷層掃描
  • 超音波影像
    • 生物顯微鏡
    • 經顱都卜勒

第9章：依患者類型分類的腦部影像市場

  • 成人
  • 兒童
  • 嬰兒

第10章：腦影像市場：依應用領域分類

  • 診斷
    • 癲癇
    • 神經退化性疾病
    • 創傷性腦損傷
    • 腫瘤檢測
    • 血管疾病
  • 研究
    • 腦圖譜
    • 神經科學
      • 基礎研究
      • 臨床研究
    • 藥物研發
  • 治療監測
    • 追蹤疾病進展
    • 手術監測
    • 治療效果評估

第11章：腦部影像市場：依最終用戶分類

  • 學術機構
    • 醫學院
    • 大學
  • 門診部
  • 診斷中心
  • 居家醫療
  • 醫院
  • 研究機構
    • 政府研究機構
    • 私人研究機構

第12章：腦造影市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：腦部影像市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 腦部影像市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國腦部影像市場

第16章：中國腦部影像診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Advantis Medical Imaging
  • AiM Medical Robotics
  • Boston Scientific Corporation
  • Bruker Corporation
  • Canon Medical Systems Corporation
  • Elekta AB
  • EMVision Medical Devices Ltd.
  • Esaote SpA
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Hitachi, Ltd.
  • Hologic, Inc.
  • Hyperfine Research, Inc.
  • Magnetic Insight, Inc.
  • Medtronic PLC
  • Octave Biosciences
  • Promaxo, Inc.
  • Royal Philips
  • Shimadzu Corporation
  • Siemens AG
  • Thermo Fisher Scientific Inc.
  • Toshiba Corporation
Product Code: MRR-5C6F41F5AF90

The Brain Imaging Modalities Market was valued at USD 15.37 billion in 2025 and is projected to grow to USD 16.90 billion in 2026, with a CAGR of 10.55%, reaching USD 31.04 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.37 billion
Estimated Year [2026] USD 16.90 billion
Forecast Year [2032] USD 31.04 billion
CAGR (%) 10.55%

An authoritative overview of contemporary brain imaging technologies and how convergence of modalities is reshaping clinical care and neuroscience research pathways

The study of brain imaging has matured into a multidisciplinary field that sits at the intersection of clinical neurology, surgical practice, neuroscience research, and biomedical engineering. Advances in instrumentation, data analytics, and tracer chemistry have expanded the portfolio of available modalities while elevating the clinical precision with which clinicians diagnose, monitor, and treat neurological disorders. As a result, imaging now informs everything from acute intervention planning to long-term therapeutic monitoring and basic mechanistic inquiry.

Technological refinements have driven improvements in spatial and temporal resolution, reduced acquisition times, and enabled safer, more patient-centric workflows, which in turn facilitate broader clinical adoption. Simultaneously, the proliferation of multimodal imaging approaches and integrated analytical pipelines has created new opportunities for cross-disciplinary collaboration, allowing clinicians and researchers to combine structural, functional, molecular, and hemodynamic information in a single diagnostic narrative. Consequently, imaging is increasingly central to personalized care pathways and to translational research paradigms that aim to close the gap between bench and bedside.

Looking ahead, implementation of scalable data standards, validation frameworks, and interoperable platforms will determine how rapidly new technologies translate into routine clinical use. With attention to regulatory compliance, reimbursement patterns, and clinician training, organizations can navigate the complexity of modality choice, clinical indication, and operational constraints to deliver measurable improvements in diagnostic accuracy and patient outcomes.

How advances in AI, portable instrumentation, hybrid imaging tracers, and interoperable analytics are reshaping clinical practice, research workflows, and diagnostic confidence

A number of transformative shifts are reconfiguring the brain imaging landscape, driven by technological innovation, data science, and evolving clinical needs. Artificial intelligence and advanced image analytics now augment human interpretation, enabling improved detection of subtle pathophysiology and the extraction of quantitative biomarkers that were previously inaccessible. At the same time, hardware innovation-such as higher field magnetic resonance systems, compact computed tomography units, and portable ultrasound-has expanded where and how imaging can be delivered, moving diagnostic capability closer to point-of-care settings.

Concurrently, molecular imaging tracers and hybrid systems have refined the capacity for in vivo biochemical mapping, which enhances diagnostic specificity for conditions such as neurodegenerative disease and focal epileptogenic zones. Integration between structural and functional modalities supports more accurate surgical planning and targeted therapeutic monitoring, while optical techniques have opened non-invasive windows for bedside neurovascular and hemodynamic assessment. As interoperability standards and cloud-native platforms mature, multi-site data aggregation increases the statistical power of research studies and accelerates clinical validation of novel biomarkers.

Consequently, stakeholders must adapt to an environment where technological choices are inseparable from data governance, clinical workflow redesign, and workforce competency. Providers that invest in scalable infrastructure, validate AI tools against robust ground truth, and cultivate multidisciplinary teams will capture the greatest clinical and operational value from these shifts.

Assessment of how the 2025 tariff environment reshaped supply reliability, procurement strategies, and research continuity for brain imaging stakeholders

Policy shifts enacted through tariff changes in 2025 created pronounced ripple effects across the global supply chain for brain imaging hardware, consumables, and ancillary services. Increased import duties on specialized components elevated lead times for large equipment and intermittent components, prompting manufacturers and health systems to reassess sourcing strategies. As a result, procurement cycles lengthened and capital planning required greater contingency buffering to maintain scheduled upgrades and installations.

Moreover, tariffs had heterogeneous effects across product categories. High-precision manufacturing elements used in computed tomography gantries, magnetic resonance gradient systems, and PET/SPECT detectors experienced supply pressure, whereas software and digital services, which predominantly travel electronically, were less directly affected. Consequently, some providers prioritized modular upgrades and software-driven improvements as near-term mitigations while deferring hardware refreshes. Research institutions were particularly sensitive to customs delays affecting radiochemistry kits and tracers used in molecular imaging, which complicated study timelines and regulatory submissions.

In response, industry actors accelerated diversification of manufacturing footprints, increased inventory of critical spares, and expanded regional partnerships to localize production where feasible. Simultaneously, strategic collaboration between device manufacturers, logistics providers, and clinical purchasers became essential to ensure continuity of service and to protect sensitive research schedules. Going forward, adaptations in procurement strategy, contract design, and supply chain visibility will remain central to managing policy-driven disruptions.

Deep segmentation insights synthesizing modality differences, application needs, and end-user constraints to guide procurement, R&D, and clinical deployment strategies

Segmentation-driven insights reveal nuanced patterns of adoption, clinical utility, and research allocation across modality, application, and end user dimensions. Based on modality, the landscape includes Computed Tomography, Magnetic Resonance Imaging, Optical Imaging, Positron Emission Tomography, Single Photon Emission Computer Tomography, and Ultrasound Imaging; within Computed Tomography, distinctions between Cone Beam and Conventional systems influence choices for interventional and surgical guidance, whereas Magnetic Resonance Imaging subdivides into Angiography, Diffusion, Functional, and Structural techniques that support vascular, white matter, functional connectivity, and anatomical assessments. Similarly, Optical Imaging encompasses functional near-infrared spectroscopy and optical coherence tomography, and Positron Emission Tomography differentiates among tracers such as amyloid, dopamine, and FDG, with Single Photon Emission Computer Tomography frequently focused on dopamine transporter imaging. Ultrasound Imaging remains bifurcated between biomicroscopy for high-resolution ocular and superficial tissue applications and transcranial Doppler for hemodynamic monitoring.

Based on application, the primary categories encompass Diagnostics, Research, and Therapeutic Monitoring; diagnostic subdomains include epilepsy, neurodegenerative disorders, traumatic brain injury, tumor detection, and vascular disease, each demanding specific modality strengths and tailored acquisition protocols. The research domain spans brain mapping, neuroscience, and pharmaceutical development, with neuroscience further divided into basic and clinical research, highlighting distinct validation, reproducibility, and ethics considerations. Therapeutic monitoring focuses on disease progression tracking, surgical monitoring, and treatment response assessment, where longitudinal consistency and biomarker robustness are critical to clinical decision making.

Based on end user, the ecosystem comprises academic institutions, ambulatory care facilities, diagnostic centers, home healthcare, hospitals, and research institutes; academic institutions further include medical schools and universities, while research institutes encompass government and private lab operators. Each end user has unique capital constraints, workflow needs, and regulatory exposures that shape procurement priorities. For example, academic and research settings prioritize flexible, high-throughput platforms and data accessibility for hypothesis generation, whereas hospitals emphasize integrated PACS, streamlined workflows, and reimbursement alignment for routine diagnostic throughput. Ambulatory and home care settings increasingly adopt compact and portable options that support decentralized patient pathways, and diagnostic centers balance cost efficiency with specialization to attract referral traffic.

Taken together, these segmentation layers demonstrate that modality choice cannot be decoupled from clinical indication, operational context, or end-user constraints. Stakeholders should therefore align procurement and development strategies to the specific demands of the modality-application-end user nexus to maximize clinical impact and operational efficiency.

Regional strategic considerations emphasizing how adoption, regulation, infrastructure, and supply chain localization differ across the Americas, EMEA, and Asia-Pacific

Regional dynamics shape adoption curves, regulatory timelines, infrastructure investment, and supply chain resilience in distinct ways across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinical consolidation, high levels of private investment, and established reimbursement pathways support rapid uptake of advanced imaging capabilities, particularly in tertiary hospital settings and research hubs. Conversely, this region also faces pressures from capital cycle optimization and an increased emphasis on value-based procurement, which drives interest in solutions that demonstrate clear outcomes and operational efficiencies.

In Europe Middle East & Africa, heterogeneous regulatory landscapes and variable infrastructure maturity lead to differentiated adoption patterns. Western European centers continue to lead in high-field MRI and molecular imaging applications, supported by integrated clinical research networks, while pockets in the Middle East and Africa show targeted investments in imaging infrastructure aimed at building regional centers of excellence. Cross-border collaboration and harmonized clinical trials are increasingly important, and stakeholders must navigate a patchwork of reimbursement regimes and data protection requirements to scale solutions continentally.

Asia-Pacific displays a dynamic mix of rapid technology adoption in urban tertiary centers, government-led modernization programs, and an expanding landscape of domestic manufacturers. High patient volumes accelerate innovation in throughput optimization and cost-effective imaging solutions, and regulatory bodies are increasingly aligning with international standards to support clinical trials and cross-jurisdictional device approval. Across all regions, local workforce training, supply chain localization, and culturally tailored clinical pathways remain critical to sustaining adoption and maximizing health system impact.

How corporate strategies, partnerships, and platform approaches are converging to accelerate validation and commercial adoption of advanced brain imaging solutions

Corporate behavior in the brain imaging ecosystem reflects a blend of capability consolidation, strategic partnerships, and targeted innovation aimed at closing clinical gaps. Established device manufacturers continue to prioritize integration of advanced image processing, AI-augmented interpretation, and service models that bundle equipment with lifecycle support. At the same time, specialized vendors and start-ups concentrate on niche capabilities such as tracer development, optical imaging modules, or advanced post-processing analytics, carving out value by addressing unmet clinical or research needs.

Partnerships between hardware suppliers, software developers, and clinical centers accelerate validation pathways and reduce time to adoption. These collaborations often include co-development agreements, joint clinical validation studies, and shared data access arrangements that facilitate regulatory submissions and broaden the evidence base. In parallel, companies are increasingly exploring as-a-service commercial models to lower barriers to adoption and to create recurring revenue streams that align vendor incentives with clinical outcomes.

Finally, corporate strategies that emphasize open platforms, interoperable standards, and clinician-centric workflows tend to achieve stronger adoption in complex health systems. Organizations that invest in transparent evidence generation, robust post-market surveillance, and scalable customer support position themselves to capture long-term value as imaging becomes more central to personalized neurology and translational research.

Practical, high-impact recommendations for executives and clinical leaders to strengthen resilience, validate innovations, and accelerate safe adoption of imaging advances

Industry leaders should adopt a pragmatic, action-oriented playbook that balances near-term operational resilience with long-term clinical innovation. First, diversify procurement and manufacturing relationships to reduce exposure to supply chain shocks and policy shifts, while simultaneously investing in inventory visibility tools that enable anticipatory sourcing. Second, prioritize interoperability and standards compliance when selecting imaging hardware and software to protect future investment and to streamline multi-site research collaborations.

Third, integrate AI and analytics through rigorous validation pipelines that include independent clinical testing, explainability assessments, and continuous performance monitoring in real-world settings. Fourth, align product development and clinical implementation with clear use case definitions and outcome metrics so that value can be demonstrated to payers and health system decision makers. Fifth, commit to workforce development by funding clinician training programs and cross-disciplinary teams that bridge radiology, neurology, and data science; this will accelerate uptake and ensure safe, effective utilization.

Lastly, pursue collaborative models that involve clinicians early in product design, leverage public-private partnerships for tracer and protocol development, and explore innovative commercial frameworks such as outcome-linked agreements. By taking these actions, organizations will be better positioned to convert technological advances into sustainable clinical and commercial value.

An integrated, multi-method research framework combining literature synthesis, expert interviews, device evidence, and scenario analysis to inform strategic decisions

The underlying research approach integrates multiple evidence streams to yield a robust and defensible analysis of the brain imaging landscape. Primary methodologies include systematic review of peer-reviewed literature, regulatory filings, and clinical trial registries, complemented by structured interviews with clinical experts, imaging scientists, procurement officers, and technology vendors. The synthesis draws on device performance specifications, tracer chemistry reports, and operational case studies to map technology capabilities to clinical and research use cases.

Data triangulation is a central pillar of the method, combining qualitative expert insight with quantitative indicators such as equipment deployment patterns, trial enrollment distributions, and citation-based scholarly activity. Scenario analysis is used to assess the implications of external drivers-such as policy shifts, reimbursement changes, and supply chain disruptions-while sensitivity assessments identify which variables have the greatest operational impact under alternative assumptions. Finally, ethical, regulatory, and data governance considerations are evaluated to ensure that recommendations are aligned with prevailing clinical standards and patient safety norms.

A concise synthesis of technological advances, operational imperatives, and strategic priorities that will determine clinical and research success in brain imaging

In summary, advances in imaging hardware, tracer chemistry, and analytics are collectively expanding the diagnostic and research capabilities available to clinicians and scientists. These advances create opportunities for more precise disease characterization, improved surgical planning, and robust therapeutic monitoring, but they also demand intentional investments in interoperability, validation, and workforce readiness. Policy developments and supply chain shifts emphasize the need for diversified procurement strategies and for closer collaboration between vendors and clinical operators.

For stakeholders across hospitals, research institutes, and commercial organizations, the imperative is to translate technological potential into reproducible clinical value through disciplined evidence generation and patient-centered implementation. By focusing on validated use cases, standardized data practices, and multisector partnerships, organizations can deploy imaging innovations that improve outcomes, reduce diagnostic uncertainty, and support translational research agendas. The future of brain imaging will be defined less by individual technologies and more by the systems that integrate them safely, efficiently, and equitably.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Imaging Modalities Market, by Modality

  • 8.1. Computed Tomography
    • 8.1.1. Cone Beam
    • 8.1.2. Conventional
  • 8.2. Magnetic Resonance Imaging
    • 8.2.1. Angiography
    • 8.2.2. Diffusion
    • 8.2.3. Functional
    • 8.2.4. Structural
  • 8.3. Optical Imaging
    • 8.3.1. Fnirs
    • 8.3.2. Optical Coherence Tomography
  • 8.4. Positron Emission Tomography
    • 8.4.1. Amyloid
    • 8.4.2. Dopamine
    • 8.4.3. Fdg
  • 8.5. Single Photon Emission Computer Tomography
  • 8.6. Ultrasound Imaging
    • 8.6.1. Biomicroscopy
    • 8.6.2. Transcranial Doppler

9. Brain Imaging Modalities Market, by Patient Type

  • 9.1. Adults
  • 9.2. Pediatrics
  • 9.3. Infants

10. Brain Imaging Modalities Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. Epilepsy
    • 10.1.2. Neurodegenerative Disorders
    • 10.1.3. Traumatic Brain Injury
    • 10.1.4. Tumor Detection
    • 10.1.5. Vascular Disease
  • 10.2. Research
    • 10.2.1. Brain Mapping
    • 10.2.2. Neuroscience
      • 10.2.2.1. Basic Research
      • 10.2.2.2. Clinical Research
    • 10.2.3. Pharmaceutical Development
  • 10.3. Therapeutic Monitoring
    • 10.3.1. Disease Progression Tracking
    • 10.3.2. Surgical Monitoring
    • 10.3.3. Treatment Response Assessment

11. Brain Imaging Modalities Market, by End User

  • 11.1. Academic Institutions
    • 11.1.1. Medical Schools
    • 11.1.2. Universities
  • 11.2. Ambulatory Care Facilities
  • 11.3. Diagnostic Centers
  • 11.4. Home Healthcare
  • 11.5. Hospitals
  • 11.6. Research Institutes
    • 11.6.1. Government Labs
    • 11.6.2. Private Labs

12. Brain Imaging Modalities Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Brain Imaging Modalities Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Brain Imaging Modalities Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Brain Imaging Modalities Market

16. China Brain Imaging Modalities Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Advantis Medical Imaging
  • 17.7. AiM Medical Robotics
  • 17.8. Boston Scientific Corporation
  • 17.9. Bruker Corporation
  • 17.10. Canon Medical Systems Corporation
  • 17.11. Elekta AB
  • 17.12. EMVision Medical Devices Ltd.
  • 17.13. Esaote SpA
  • 17.14. Fujifilm Holdings Corporation
  • 17.15. GE HealthCare Technologies, Inc.
  • 17.16. Hitachi, Ltd.
  • 17.17. Hologic, Inc.
  • 17.18. Hyperfine Research, Inc.
  • 17.19. Magnetic Insight, Inc.
  • 17.20. Medtronic PLC
  • 17.21. Octave Biosciences
  • 17.22. Promaxo, Inc.
  • 17.23. Royal Philips
  • 17.24. Shimadzu Corporation
  • 17.25. Siemens AG
  • 17.26. Thermo Fisher Scientific Inc.
  • 17.27. Toshiba Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN IMAGING MODALITIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN IMAGING MODALITIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BRAIN IMAGING MODALITIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BRAIN IMAGING MODALITIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONE BEAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONE BEAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONE BEAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ANGIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ANGIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ANGIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIFFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIFFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIFFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FUNCTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FUNCTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FUNCTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY STRUCTURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY STRUCTURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY STRUCTURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FNIRS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FNIRS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FNIRS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMYLOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMYLOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMYLOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FDG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FDG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FDG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BIOMICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BIOMICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BIOMICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY INFANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY INFANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TUMOR DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TUMOR DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TUMOR DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY VASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY VASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY VASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BRAIN MAPPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BRAIN MAPPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BRAIN MAPPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DISEASE PROGRESSION TRACKING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DISEASE PROGRESSION TRACKING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DISEASE PROGRESSION TRACKING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SURGICAL MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SURGICAL MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SURGICAL MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TREATMENT RESPONSE ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TREATMENT RESPONSE ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TREATMENT RESPONSE ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MEDICAL SCHOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MEDICAL SCHOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MEDICAL SCHOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY GOVERNMENT LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY GOVERNMENT LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PRIVATE LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PRIVATE LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 290. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY END U